Navigation Links
Drug Proves Effective in Slowing Melanomas
Date:4/15/2008

Riluzole, used to treat Lou Gehrig's disease, inhibits aggressive growth, study finds

TUESDAY, April 15 (HealthDay News) -- The drug riluzole, approved in the United States to treat amyotrophic lateral sclerosis (ALS), slows the growth of highly aggressive melanoma skin cancer, according to a new study.

A common feature of both melanoma and ALS (also called Lou Gehrig's disease) is an excess amount of the protein glutamate, a cellular growth factor or food for cells. Too much glutamate can overstimulate neurons to the point where they burn out -- a possible explanation for what happens in ALS, according to background information in the study. Overproduction of glutamate causes the growth and expansion of melanoma.

Riluzole (brand name Rilutek) inhibits the release of glutamate.

In laboratory tests using cultures of human melanoma cell lines, researchers at Rutgers University and the Cancer Institute of New Jersey found that riluzole appeared to switch off overproduction of glutamate and slow the growth rate of the melanoma cells. In tests on animals, the drug showed the same suppression of melanoma cell growth.

The researchers then started testing the drug on 11 people with late-stage (stage 3 or 4) melanoma. The patients in this phase 0 (exploratory, first-in-humans) trial received riluzole for two weeks.

"Our preliminary results show three solid positive responses in nine of the patients who had been able to complete the trial to date," Dr. James Goydos, a surgical oncologist at the Cancer Institute of New Jersey, said in a prepared statement.

Other patients in the group showed some indications of responding to the drug, and they'll be reassessed at the end of the trial.

The research was to be presented April 15 at the annual meeting of the American Association for Cancer Research, in San Diego.

The findings provide "enough data to show that we should go on to a
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. Nasal Anthrax Vaccine Proves Effective in Animal Study
3. FDA Approves New Roche West Nile Virus Blood Screening Test
4. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
5. Exercise and yoga improves quality of life in women with early-stage breast cancer
6. Toddler Study Proves Humans Outsmart Apes
7. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
8. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
9. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
10. FDA Approves SOMA(R) (carisoprodol) 250 mg
11. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... my mom’s stroke, she loss the use of her right side. ... his left side. Eating became a difficult task for them so ... enjoy eating again,” said an inventor, from Fayetteville, N.C. As a ... (P C H PLATE). , The PATRICIA CAROL HALL PLATE (P ... individuals who suffer from stroke, experience tremors or loss of movement. ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... to move forward in U.S. courts, Bernstein Liebhard LLP ... elevated metal ion levels to the failure of metal-on-metal ... 2nd issue of The Journal of Bone & Joint ... received unilateral Articular Surface Replacement prostheses at least twelve ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 For those who ... bodies can readily absorb the nutrients in food. The enzymes ... that are small enough to be absorbed by human bodies. ... a lack of enzymes in regular food is the cause ... product that was started by Michelle DelPresto, a mother of ...
(Date:7/12/2014)... 2014 “Critical Care Therapeutics in ... Late-Stage Four-Factor PCCs and Recombinant Products to Drive ... care market in the US, UK, France, Germany, ... an estimation of market size for 2013, along ... care indications that are being treated using the ...
(Date:7/12/2014)... 2014 As reported in this July ... and Technology), the June 25th, 2014 Supreme Court ruling in ... world. It was also met with both cheers and ... it was seen from an individual privacy perspective, or a ... there is now precedent which will require law enforcement officials ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5
... during college, survey shows , , MONDAY, July 7 (HealthDay ... common before and during college, a new study shows. ... (57.1 percent female) at three urban college campuses to ... , 407 (44.7 percent) of respondents said they experienced ...
... the risk seems bigger if certain painkillers are ... News) -- The widely prescribed class of antidepressants ... in the upper gastrointestinal tract, especially when taken ... study says. , Although reports of this effect ...
... Preserve Vital Stem Cells During, Their Menstrual Flow; Potential for Future Anti-Aging ... ... Fla., July 7 With today,s hectic,lifestyle, where most women are juggling ... a serious illness in,the future is not something that readily comes to ...
... HARRISBURG, Pa., July 7 Need to find ... area? Are you,a senior citizen living in Pennsylvania ... information on oral health topics such as,brushing and ... no,further! PDA,s website, http://www.padental.org, is an ...
... CCA Industries,Inc. (Amex: CAW ) declared today a ... shareholders of record as of August 1, 2008, payable on,September ... 31, 2008 were $17,389,985.,Net income was $790,692 and earnings per ... of $1,292,921 and earnings per,share of $0.18 fully diluted for ...
... In a New York City metro-area first, a 93-year-old ... at NewYork-Presbyterian Hospital, the only center on the Eastern ... new stent graft was implanted under an FDA-approved clinical ... a complex form of abdominal aortic aneurysms in which ...
Cached Medicine News:Health News:Relationship Violence Common Among College Students 2Health News:Popular Antidepressants Linked to GI Bleeding 2Health News:Popular Antidepressants Linked to GI Bleeding 3Health News:Taking Control: Future Therapies for a Host of Serious Diseases May Be Found in Women's Menstrual Blood 2Health News:Pennsylvania Dental Association Website: A Great Resource for Pennsylvania Residents 2Health News:CCA Industries, Inc. Declares Its Seventeenth Consecutive Dividend 2Health News:NYC first: Complex aneurysm treated using new fenestrated endograft stent 2
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... Israel , July 10, 2014   ... Diabetes Management Solution, today announced the appointment of ... independent member of its Board of Directors. ... legal and business experience to LabStyle as an ... and legal and corporate governance expert. He currently ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Intravenous to Subcutaneous Conversion -, SAN ... HALO ), a biopharmaceutical company developing ... new pre-clinical findings on the local tolerability ... the American,Association for Cancer Research (AACR) conference., ...
... for Novavax,s ... Influenza Vaccine Candidate, ROCKVILLE, Md., April 16 Novavax, ... positive results from an,immunogenicity study in ferrets inoculated with the ... to,complete its planned investigational new drug ("IND") application to,support initiation ...
Cached Medicine Technology:Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference 2Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference 3Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference 4Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 2Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 3
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
... Combines BchiVac V-500 with Vacuum Controller V-800 ... mechanism turns V-500 on and off as needed to ... is a powerful PTFE membrane vacuum pump designed to ... suited for use with up to two rotary evaporators ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)...
... a new addition to the powerful PTFE membrane ... pump can achieve an ultimate vacuum of 1 ... Applications For use with vacuum ... Distillation applications from lab size up to industrial ...
Medicine Products: